Triple Negative Breast Cancer (TNBC) is one of the most aggressive types of breast cancer. It’s the kind of breast cancer that doesn’t have estrogen receptors, progesterone receptors, and human ...
Real-world survival outcomes with pembrolizumab plus chemotherapy in advanced triple-negative breast cancer: Multicenter evidence from Poland, the Czech Republic, and Slovakia. This is an ASCO Meeting ...
For patients with early-stage triple-negative breast cancer (TNBC), finishing chemotherapy and surgery should feel like the end of the hardest chapter. But for many, it marks the beginning of a ...
A global, multicenter phase III trial, TROPION-Breast02, led by a senior medical oncologist and researcher from the National Cancer Centre Singapore, has demonstrated a significant breakthrough in ...
Ultrasensitive circulating tumor DNA (ctDNA) testing may help identify women with triple-negative breast cancer who are at either a very high or very low risk for recurrence after surgery, new ...
Add Yahoo as a preferred source to see more of our stories on Google. New prospective sub-study analysis data presented by Abbott at the 2026 American Society of Clinical Oncology (ASCO) meeting has ...
Editor’s note: This is an automatically generated transcript, which has been slightly edited for clarity. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.
A new PET radiotracer can effectively visualize Nectin-4, an emerging biomarker found in triple-negative breast cancer (TNBC). According to research published in the March issue of The Journal of ...
New prospective sub-study analysis data presented by Abbott at the 2026 American Society of Clinical Oncology (ASCO) meeting has highlighted the value of minimal residual disease (MRD) testing in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results